These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 32683421)

  • 1. NCAPG confers trastuzumab resistance via activating SRC/STAT3 signaling pathway in HER2-positive breast cancer.
    Jiang L; Ren L; Chen H; Pan J; Zhang Z; Kuang X; Chen X; Bao W; Lin C; Zhou Z; Huang D; Yang J; Huang H; Wang L; Hou N; Song L
    Cell Death Dis; 2020 Jul; 11(7):547. PubMed ID: 32683421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer.
    Wang L; Wang Q; Gao M; Fu L; Li Y; Quan H; Lou L
    Cancer Sci; 2018 Oct; 109(10):3305-3315. PubMed ID: 30076657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells.
    Gardaneh M; Shojaei S; Kaviani A; Behnam B
    Breast Cancer Res Treat; 2017 Apr; 162(2):231-241. PubMed ID: 28116540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer.
    Zou H; Luo J; Guo Y; Deng L; Zeng L; Pan Y; Li P
    Drug Resist Updat; 2024 Mar; 73():101051. PubMed ID: 38219531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. POU4F1 confers trastuzumab resistance in HER2-positive breast cancer through regulating ERK1/2 signaling pathway.
    Wu D; Jia HY; Wei N; Li SJ
    Biochem Biophys Res Commun; 2020 Dec; 533(3):533-539. PubMed ID: 32988584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling.
    Choi HJ; Jin S; Cho H; Won HY; An HW; Jeong GY; Park YU; Kim HY; Park MK; Son T; Min KW; Jang KS; Oh YH; Lee JY; Kong G
    EMBO Rep; 2019 Oct; 20(10):e48058. PubMed ID: 31468695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models.
    Yang L; Bhattacharya A; Peterson D; Li Y; Liu X; Marangoni E; Robila V; Zhang Y
    Drug Resist Updat; 2024 May; 74():101078. PubMed ID: 38503142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
    Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
    Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating cancer stem cell-like properties.
    Li Y; Chu J; Feng W; Yang M; Zhang Y; Zhang Y; Qin Y; Xu J; Li J; Vasilatos SN; Fu Z; Huang Y; Yin Y
    FASEB J; 2019 Apr; 33(4):4851-4865. PubMed ID: 30620624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion.
    Chaganty BKR; Qiu S; Gest A; Lu Y; Ivan C; Calin GA; Weiner LM; Fan Z
    Cancer Lett; 2018 Aug; 430():47-56. PubMed ID: 29746929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression.
    Li G; Zhao L; Li W; Fan K; Qian W; Hou S; Wang H; Dai J; Wei H; Guo Y
    Oncotarget; 2014 Sep; 5(18):8317-29. PubMed ID: 25327561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12.
    Xu W; Bi Y; Zhang J; Kong J; Jiang H; Tian M; Li K; Wang B; Chen C; Song F; Pan X; Shi B; Kong X; Gu J; Cai X; Li Z
    Oncotarget; 2015 Nov; 6(36):38840-53. PubMed ID: 26474285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation.
    Yamashita-Kashima Y; Shu S; Osada M; Fujimura T; Yoshiura S; Harada N; Yoshimura Y
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):641-654. PubMed ID: 32997196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
    Palomeras S; Diaz-Lagares Á; Viñas G; Setien F; Ferreira HJ; Oliveras G; Crujeiras AB; Hernández A; Lum DH; Welm AL; Esteller M; Puig T
    Breast Cancer Res; 2019 Jul; 21(1):79. PubMed ID: 31277676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
    Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
    BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inorganic kernel - Supported asymmetric hybrid vesicles for targeting delivery of STAT3-decoy oligonucleotides to overcome anti-HER2 therapeutic resistance of BT474R.
    Shi K; Fang Y; Gao S; Yang D; Bi H; Xue J; Lu A; Li Y; Ke L; Lin X; Jin X; Li M
    J Control Release; 2018 Jun; 279():53-68. PubMed ID: 29655990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma.
    Peiró G; Ortiz-Martínez F; Gallardo A; Pérez-Balaguer A; Sánchez-Payá J; Ponce JJ; Tibau A; López-Vilaro L; Escuin D; Adrover E; Barnadas A; Lerma E
    Br J Cancer; 2014 Aug; 111(4):689-95. PubMed ID: 24937674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition.
    Jin MH; Nam AR; Park JE; Bang JH; Bang YJ; Oh DY
    Mol Cancer Ther; 2017 Jun; 16(6):1145-1154. PubMed ID: 28223426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
    Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
    PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.